New research entertains the theory of antidepressant efficacy as early-COVID-19 treatment

A group of researchers has entertained the theory of antidepressant use for early treatment of COVID-19, with potential efficacious outcomes.

In a study published by the Lancet, researchers suggested that the antidepressant drug fluvoxamine may provide some extent of efficacy for the early treatment of COVID-19 among acutely symptomatic patients.

For the study, nearly 10,000 people were screened, as part of a clinical trial that began on June 2nd, 2020. As many as 741 participants were administered fluvoxamine, while the other 756 a placebo.

According to the Lancet study: “This is, to the best of our knowledge, the first large, randomised controlled trial to test the efficacy of fluvoxamine for acute treatment of COVID-19. We found a clinically important absolute risk reduction of 5·0%, and 32% RR reduction, on the primary outcome of hospitalization.”

Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation.”

Image courtesy of Getty Images
More Stories
Experimental drug treatment tofersen may be useful for treating inherited form of ALS